ADMA Biologics Inc (ADMA)
ADMA BIOLOGICS, INC. is an end-to-end commercial biopharmaceutical company focused on manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Co.'s products include: BIVIGAM, an Intravenous Immune Globulin (IVIG) product indicated for the treatment of Primary Humoral Immunodeficiency (PI); ASCENIV, an IVIG product indicated for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing HBsAg and other listed exposures to Hepatitis B.
ADMA SEC Filing Email Alerts Service
| Company Name: |
ADMA Biologics Inc |
| Website: |
www.admabiologics.com |
| Sector: |
Drugs & Pharmaceuticals |
| Number of ETFs Holding ADMA: |
28 |
| Total Market Value Held by ETFs: |
$161.46M |
| Total Market Capitalization: |
$1.37B |
| % of Market Cap. Held by ETFs: |
11.75% |
|
|
April 16, 2024 • 7:19 PM Eastern
Strong Buy (4.00 out of 4)
100th percentile
|
|
Free ADMA Email Alerts:
